Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gemox Combined With Anlotinib and Sintilimab in Advanced Combined Hepatocellular-cholangiocarcinoma: an Exploratory Study

NCT06033118 is registered in ClinicalTrials.gov with Sichuan University as lead sponsor.

NCT NCT06033118
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06033118 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gemox Combined With Anlotinib and Sintilimab in Advanced Combined Hepatocellular-cholangiocarcinoma: an Exploratory Study
Lead sponsor
Sichuan University
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 1, 2023
Completion date
August 1, 2026
Enrollment
25 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

combined hepatocellular cholangiocarcinoma